<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02124018</url>
  </required_header>
  <id_info>
    <org_study_id>UOA-PRESERVE1</org_study_id>
    <nct_id>NCT02124018</nct_id>
  </id_info>
  <brief_title>Risk Stratification in Patients With Preserved Ejection Fraction</brief_title>
  <acronym>PRESERVE-EF</acronym>
  <official_title>Post Myocardial Infarction Risk Stratification for Sudden Cardiac Death in Patients With Preserved Ejection Fraction: PRESERVE-EF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Electric</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Athens</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the prevalence and the prognostic value of non-invasive
      indexes and programmed ventricular stimulation for sudden cardiac death in post-myocardial
      infarction (MI) patients with left ventricular ejection fraction (LVEF)&gt;40%.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1000 asymptomatic post-MI patients&gt;40%, at least 40 days post-MI, revascularized or without
      needing further revascularization (in any case without any evidence of ischemia) will be
      enrolled.

      The patients will be divided into two categories:

        1. Asymptomatic patients with revascularized ST-elevation MI (STEMI) (remaining stenoses in
           non culprit vessels &lt;70%) at 40 days post-MI (when LVEF&gt;40% will be re-assessed)

        2. Asymptomatic patients late (at any time after 40 days) after MI (initially STEMI-NSTEMI
           at discharge Q-non Q) with LVEF&gt;40% right after a negative stress test or right after a
           negative for stenoses control coronary catheterization All patients will undergo
           non-invasive evaluation (ECG, Holter monitoring and 45-min high resolution recording).
           In case they fulfill at least one out of seven pre-specified criteria they will undergo
           programmed ventricular stimulation and implantable cardioverter-defibrillator (ICD)
           implantation (if inducible) All patients will be followed-up for 3 years for sudden
           cardiac death and its surrogate (appropriate ICD activation)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2014</start_date>
  <completion_date type="Actual">July 31, 2018</completion_date>
  <primary_completion_date type="Actual">July 31, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Number of Participants With Major Arrhythmic Events (MAEs) - Present When One of the Following Occurred: Sudden Cardiac Death, Sustained Ventricular Tachycardia, or Implantable Cardioverter - Defibrillator (ICD) Activation</measure>
    <time_frame>From stratification completion (i.e. allocation to one of three risk level groups) until either occurrence of primary endpoint or study completion (mean 32months) - study stopped early due to emergence of clearly defined high risk subgroup</time_frame>
    <description>The number of patients from each risk level group meeting the primary endpoint will be used to assess diagnostic accuracy (positive/negative predictive value, sensitivity and specificity) of the proposed two-stage, PVS-inclusive, risk stratification approach for the allocation of an ICD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Mortality</measure>
    <time_frame>From completion of risk stratification to study completion or outcome occurrence (mean 32 months)</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">575</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Post-MI patients</arm_group_label>
    <description>Asymptomatic post-MI patients late after MI or 40 days after STEMI-NSTEMI with preserved ejection fraction and absence of active ischemia Programmed ventricular stimulation (PVS) will be performed in high-risk patients based on non-invasive evaluation.
ICD implantation will be performed in patients with induced ventricular tachycardia (VT) upon PVS</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Programmed ventricular stimulation</intervention_name>
    <description>Programmed ventricular stimulation in high-risk patients based on non-invasive evaluation</description>
    <arm_group_label>Post-MI patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ICD implantation</intervention_name>
    <description>ICD implantation in patients with induced VT in programmed ventricular stimulation</description>
    <arm_group_label>Post-MI patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1000 asymptomatic post-MI patients&gt;40%, at least 40 days post-MI, revascularized or without
        needing further revascularization (in any case without any evidence of ischemia)

        The patients will be divided into two categories:

          1. Asymptomatic patients with revascularized STEMI (remaining stenoses in non culprit
             vessels &lt;70%) at 40 days post-MI (when LVEF&gt;40% will be re-assessed)

          2. Asymptomatic patients late after MI (initially STEMI-NSTEMI at discharge Q-non Q) with
             LVEF&gt;40% right after a negative stress test or right after a negative for stenoses
             control coronary catheterization
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Asymptomatic patients with revascularized STEMI (remaining stenoses in non culprit
             vessels &lt;70%) at 40 days post-MI (when LVEF&gt;40% will be re-assessed)

          -  Asymptomatic patients late after MI (initially STEMI-NSTEMI at discharge Q-non Q) with
             LVEF&gt;40% right after a negative stress test or right after a negative for stenoses
             control coronary catheterization

        Exclusion Criteria:

          -  Episodes of sustained VT or aborted sudden cardiac death (SCD) 48 hours after the
             acute MI phase.

          -  Episodes of syncope within the last 6 months

          -  Cancer, liver failure (cirrhosis), end-stage renal disease

          -  Use of anti-arrhythmic drugs other than b-blockers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konstantinos Gatzoulis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Athens, Hippokration Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Cardiology Clinic, Hippokration Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 24, 2014</study_first_submitted>
  <study_first_submitted_qc>April 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2014</study_first_posted>
  <results_first_submitted>April 16, 2019</results_first_submitted>
  <results_first_submitted_qc>July 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 26, 2019</results_first_posted>
  <last_update_submitted>August 23, 2019</last_update_submitted>
  <last_update_submitted_qc>August 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Athens</investigator_affiliation>
    <investigator_full_name>Kostantinos A. Gatzoulis</investigator_full_name>
    <investigator_title>Assoc. Professor of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>Risk stratification</keyword>
  <keyword>Sudden cardiac death</keyword>
  <keyword>Preserved ejection fraction</keyword>
  <keyword>Programmed ventricular stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 23, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT02124018/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From April 2014 to July 2018, 575 consecutive patients were enrolled in the seven Departments of Cardiology participating in the study</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Risk Group</title>
          <description>No Non-Invasive Risk Factors (NIRFs) present – no invasive programmed ventricular stimulation (PVS) performed</description>
        </group>
        <group group_id="P2">
          <title>Intermediate Risk Group</title>
          <description>At least one NIRF present – noninducible upon programmed ventricular stimulation (PVS) (no sustained ventricular tachyarrhythmia was induced i.e. either with a duration &gt;30seconds or causing hemodynamic instability necessitating termination)</description>
        </group>
        <group group_id="P3">
          <title>High Risk Group</title>
          <description>At least one NIRF present AND inducible upon PVS (sustained ventricular tachyarrhythmia was induced).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="371"/>
                <participants group_id="P2" count="111"/>
                <participants group_id="P3" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="371"/>
                <participants group_id="P2" count="111"/>
                <participants group_id="P3" count="41">Numbers do not add up to 575 (enrolled) due to refusals of programmed ventricular stimulation</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Due to some patients' refusal to be submitted to invasive programmed ventricular stimulation, 52 patients were unstratifiable (unknown if Group 2 or 3), and thus 371+111+41=523=575-52</population>
      <group_list>
        <group group_id="B1">
          <title>Low Risk Group</title>
          <description>No NIRFs present – no invasive PVS performed</description>
        </group>
        <group group_id="B2">
          <title>Intermediate Risk Group</title>
          <description>At least one NIRF present – noninducible upon PVS</description>
        </group>
        <group group_id="B3">
          <title>High Risk Group</title>
          <description>At least one NIRF present AND inducible upon PVS</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="371"/>
            <count group_id="B2" value="111"/>
            <count group_id="B3" value="41"/>
            <count group_id="B4" value="523"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="371"/>
                    <count group_id="B2" value="111"/>
                    <count group_id="B3" value="41"/>
                    <count group_id="B4" value="523"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.7" spread="10.2"/>
                    <measurement group_id="B2" value="60" spread="10.9"/>
                    <measurement group_id="B3" value="61.7" spread="9.2"/>
                    <measurement group_id="B4" value="57" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="371"/>
                    <count group_id="B2" value="111"/>
                    <count group_id="B3" value="41"/>
                    <count group_id="B4" value="523"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="314"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Greece</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="371"/>
                    <count group_id="B2" value="111"/>
                    <count group_id="B3" value="41"/>
                    <count group_id="B4" value="523"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="371"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Major Arrhythmic Events (MAEs) - Present When One of the Following Occurred: Sudden Cardiac Death, Sustained Ventricular Tachycardia, or Implantable Cardioverter - Defibrillator (ICD) Activation</title>
        <description>The number of patients from each risk level group meeting the primary endpoint will be used to assess diagnostic accuracy (positive/negative predictive value, sensitivity and specificity) of the proposed two-stage, PVS-inclusive, risk stratification approach for the allocation of an ICD</description>
        <time_frame>From stratification completion (i.e. allocation to one of three risk level groups) until either occurrence of primary endpoint or study completion (mean 32months) - study stopped early due to emergence of clearly defined high risk subgroup</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Risk Group</title>
            <description>No NIRFs present – no invasive PVS performed</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Risk Group</title>
            <description>At least one NIRF present – noninducible upon PVS</description>
          </group>
          <group group_id="O3">
            <title>High Risk Group</title>
            <description>At least one NIRF present AND inducible upon PVS.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Arrhythmic Events (MAEs) - Present When One of the Following Occurred: Sudden Cardiac Death, Sustained Ventricular Tachycardia, or Implantable Cardioverter - Defibrillator (ICD) Activation</title>
          <description>The number of patients from each risk level group meeting the primary endpoint will be used to assess diagnostic accuracy (positive/negative predictive value, sensitivity and specificity) of the proposed two-stage, PVS-inclusive, risk stratification approach for the allocation of an ICD</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="371"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Mortality</title>
        <description>All-cause mortality</description>
        <time_frame>From completion of risk stratification to study completion or outcome occurrence (mean 32 months)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Risk Group</title>
            <description>No Non-Invasive Risk Factors (NIRFs) present – no invasive programmed ventricular stimulation (PVS) performed</description>
          </group>
          <group group_id="O2">
            <title>Intermediate Risk Group</title>
            <description>At least one NIRF present – noninducible upon programmed ventricular stimulation (PVS) (no sustained ventricular tachyarrhythmia was induced i.e. either with a duration &gt;30seconds or causing hemodynamic instability necessitating termination)</description>
          </group>
          <group group_id="O3">
            <title>High Risk Group</title>
            <description>At least one NIRF present AND inducible upon PVS (sustained ventricular tachyarrhythmia was induced).</description>
          </group>
        </group_list>
        <measure>
          <title>Total Mortality</title>
          <description>All-cause mortality</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="371"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From stratification completion (allocation to one of risk level groups) to adverse event occurrence, or study completion - mean 32 months</time_frame>
      <desc>Adverse events due to PVS and ICD implantation</desc>
      <group_list>
        <group group_id="E1">
          <title>Low Risk Group</title>
          <description>No NIRFs present – no invasive PVS performed</description>
        </group>
        <group group_id="E2">
          <title>Intermediate Risk Group</title>
          <description>At least one NIRF present – noninducible upon PVS</description>
        </group>
        <group group_id="E3">
          <title>High Risk Group</title>
          <description>At least one NIRF present AND inducible upon PVS.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="371"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was not a randomized clinical trial since almost all patients with a per protocol indication received a device, without the presence of a high-risk control group, thus potentially overestimating true arrhythmic risk.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Professor Konstantinos A. Gatzoulis</name_or_title>
      <organization>First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens</organization>
      <phone>6944580369 ext 0030</phone>
      <email>kgatzoul@med.uoa.gr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

